Murphy BR - Search Results

1

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC. Karron RA, et al. Among authors: murphy br. Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14. Vaccine. 2012. PMID: 22178099 Free PMC article.

2

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.

Skiadopoulos MH, Tatem JM, Surman SR, Mitcho Y, Wu SL, Elkins WR, Murphy BR. Skiadopoulos MH, et al. Among authors: murphy br. Vaccine. 2002 Mar 15;20(13-14):1846-52. doi: 10.1016/s0264-410x(02)00038-5. Vaccine. 2002. PMID: 11906774

3

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. Karron RA, et al. Among authors: murphy br. J Infect Dis. 2005 Apr 1;191(7):1093-104. doi: 10.1086/427813. Epub 2005 Mar 1. J Infect Dis. 2005. PMID: 15747245 Clinical Trial.

4

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH. Bartlett EJ, et al. Among authors: murphy br. Vaccine. 2005 Sep 7;23(38):4631-46. doi: 10.1016/j.vaccine.2005.04.035. Vaccine. 2005. PMID: 15951066

5

Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.

Nolan SM, Surman SR, Amaro-Carambot E, Collins PL, Murphy BR, Skiadopoulos MH. Nolan SM, et al. Among authors: murphy br. Vaccine. 2005 Sep 15;23(39):4765-74. doi: 10.1016/j.vaccine.2005.04.043. Vaccine. 2005. PMID: 15964103

6

Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.

Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH. Bartlett EJ, et al. Among authors: murphy br. Vaccine. 2006 Mar 24;24(14):2674-84. doi: 10.1016/j.vaccine.2005.10.047. Epub 2005 Nov 15. Vaccine. 2006. PMID: 16364511

7

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF. Madhi SA, et al. Among authors: murphy br. Vaccine. 2006 Mar 20;24(13):2432-9. doi: 10.1016/j.vaccine.2005.12.002. Epub 2005 Dec 20. Vaccine. 2006. PMID: 16406170 Clinical Trial.

8

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A. Nolan SM, et al. Among authors: murphy br. Vaccine. 2007 Aug 21;25(34):6409-22. doi: 10.1016/j.vaccine.2007.06.028. Epub 2007 Jul 3. Vaccine. 2007. PMID: 17658669 Free PMC article.

Previously, we identified several attenuating mutations in the L polymerase protein of human parainfluenza virus type 2 (HPIV2) and genetically stabilized those mutations using reverse genetics [Nolan SM, Surman S, Amaro-Carambot E, Collins PL, Murphy BR, Skiadopoul …

Previously, we identified several attenuating mutations in the L polymerase protein of human parainfluenza virus type 2 (HPIV2) and genetica …

9

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.

Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR. Wright PF, et al. Among authors: murphy br. Vaccine. 2007 Oct 16;25(42):7372-8. doi: 10.1016/j.vaccine.2007.08.014. Epub 2007 Aug 28. Vaccine. 2007. PMID: 17868959 Free PMC article.

10

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

DiNapoli JM, Ward JM, Cheng L, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. DiNapoli JM, et al. Among authors: murphy br. Vaccine. 2009 Mar 4;27(10):1530-9. doi: 10.1016/j.vaccine.2009.01.009. Epub 2009 Jan 23. Vaccine. 2009. PMID: 19168110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

440 results

Search Page

Filters